Eyevensys, a Paris, France and Cambridge MA-based biotechnology company developing non-viral gene therapies for ophthalmic diseases, raised $12M in Series B+ funding.
The round was led by Korea Investment Partners.
The company intends to use the funds for the development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye. Additionally, Eyevensys will advance its EYS611 program targeting geographic atrophy (GA) and retinitis pigmentosa.
Founded in 2008 and led by Dr. Patricia Zilliox, Eyevensys is advancing a non-viral gene therapy ocular drug delivery platform that uses an Electrotransfection System to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle to sustainably treat major eye diseases.
The company has validated its electrotransfection technology in the clinic through its EYS606 program for non-infectious uveitis, a sight-threatening intraocular inflammatory condition characterized by inflammation of the uvea. This same Electrotransfection System will be used to deliver relevant therapeutic proteins to the eye for the other EYS809 and EYS611 programs.
The company is also funded by the Boehringer Ingelheim Venture Fund, Pureos Bioventures, Bpifrance through the Innobio Fund, Karista, Inserm Transfert Initiative, Pontifax and the Global Health Sciences Fund.